Wide spetcrum mutational analysis of metastatic renal cell cancer: A retrospective next generation sequencing approach

Oncotarget

Volumn 8, Issue 5, 2017, Pages 7328-7335

  Fiorentino, Michelangelo ^a   Gruppioni, Elisa ^a   Massari, Francesco ^a   Giunchi, Francesca ^a   Altimari, Annalisa ^a   Ciccarese, Chiara ^c   Bimbatti, Davide ^c   Scarpa, Aldo ^c   Iacovelli, Roberto ^c   Porta, Camillo ^d   Virinder, Sarhadi ^b   Tortora, Giampaolo ^c   Artibani, Walter ^c   Schiavina, Riccardo ^a   Ardizzoni, Andrea ^a   Brunelli, Matteo ^c   Knuutila, Sakari ^b   Martignoni, Guido ^c  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF HELSINKI   (Finland)

^c UNIVERSITY OF VERONA   (Italy)

^d UNIVERSITY OF PAVIA   (Italy)

Author keywords

Metastatic disease; Next generation sequencing; Pathology section; Renal cell carcinoma; Target therapy; VHL

Indexed keywords

SORAFENIB; SUNITINIB; TEMSIROLIMUS; ANTINEOPLASTIC AGENT; PROTEIN KINASE INHIBITOR; TUMOR MARKER;

ADULT; AGED; APC GENE; ARTICLE; CANCER CHEMOTHERAPY; CDKN2A GENE; CLINICAL ARTICLE; EGFR GENE; ERBB4 GENE; FEMALE; FGFR3 GENE; GENE; GENOTYPE; HUMAN; JAK3 GENE; KIDNEY METASTASIS; MALE; MET GENE; MIDDLE AGED; MUTATIONAL ANALYSIS; NEXT GENERATION SEQUENCING; PTEN GENE; RB1 GENE; RETROSPECTIVE STUDY; SOMATIC MUTATION; TP53 GENE; VHL GENE; WILD TYPE; CLINICAL TRIAL; DNA MUTATIONAL ANALYSIS; GENETIC PREDISPOSITION; GENETICS; HIGH THROUGHPUT SEQUENCING; ITALY; KIDNEY TUMOR; MULTICENTER STUDY; MUTATION; PATHOLOGY; PATIENT SELECTION; PERSONALIZED MEDICINE; PHENOTYPE; PREDICTIVE VALUE; PROCEDURES; RENAL CELL CARCINOMA; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BIOMARKERS, TUMOR; CARCINOMA, RENAL CELL; DNA MUTATIONAL ANALYSIS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; ITALY; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; MUTATION; PATIENT SELECTION; PHENOTYPE; PRECISION MEDICINE; PREDICTIVE VALUE OF TESTS; PROTEIN KINASE INHIBITORS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 85018913616     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.12551     Document Type: Article

References (22)

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin 2016;66:7-30
2. Basso M, Cassano A, Barone C. A survey of therapy for advanced renal cell carcinoma. Urol Oncol. 2010 Mar-Apr;28(2):121-33
3. Von Roemeling CA, Marlow LA, Radisky DC. Functional genomics identifies novel genes essential for clear cell renal cell carcinoma tumor cell proliferation and migration. Oncotarget. 2014; 5:5320-34. doi: 10.18632/oncotarget.2097
4. Gerlinger M, Rowan AJ, Horswell S. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med. 2012 Mar 8;366(10):883-92
5. Huang Y, Gao S, Wu S. Multilayered molecular profiling supported the monoclonal origin of metastatic renal cell carcinoma. Int J Cancer. 2014 Jul 1;135(1):78-87
6. Chen F, Zhang Y, Senbabaoglu Y, Ciriello G, Yang L, Reznik E, Shuch B, Micevic G, De Velasco G, Shinbrot E, Noble MS, Lu Y, Covington KR, et al. Multilevel Genomics-Based Taxonomy of Renal Cell Carcinoma. Cell Rep. 2016 Mar 15;14(10):2476-89. celrep.2016.02.024. Epub 2016 Mar 3
7. Brugarolas J. Molecular genetics of clear-cell renal cell carcinoma. J Clin Oncol. 2014 Jun 20;32(18):1968-76. Epub 2014 May 12
8. Powles T. Second-line therapy after VEGF targeted therapy in metastatic renal cancer: a law of diminishing returns. Clin Genitourin Cancer 2012;10:67-8
9. Cancer Genome Atlas Research Network. Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature. 2013 Jul 4;499(7456):43-9. Epub 2013 Jun 23
10. Cancer Genome Atlas Research Network, Linehan WM, Spellman PT, Ricketts CJ, Creighton CJ, Fei SS, Davis C, Wheeler DA, Murray BA, Schmidt L, Vocke CD, Peto M, Al Mamun AA, Shinbrot E, et al. Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. N Engl J Med. 2016 Jan 14;374(2):135-45. Epub 2015 Nov 4
11. Dornbusch J, Zacharis A, Meinhardt M, Erdmann K, Wolff I, Froehner M, Wirth MP, Zastrow S, Fuessel S. Analyses of potential predictive markers and survival data for a response to sunitinib in patients with metastatic renal cell carcinoma. PLoS One. 2013 Sep 27;8(9):e76386. eCollection 2013
12. Moch, H, Humphrey PA, Ulbright TM, Reuter VE. WHO classification of the tumours of the urinary system and male genital organs. International Agency for Research on Cancer, Lyon, 2016. Chapter 1: 13-76
13. Durinck S, Stawiski EW, Pavía-Jiménez A, Modrusan Z, Kapur P, Jaiswal BS, Zhang N, Toffessi-Tcheuyap V, Nguyen TT, Pahuja KB, Chen YJ, Saleem S, Chaudhuri S, et al. Spectrum of diverse genomic alterations define non-clear cell renal carcinoma subtypes. Nat Genet. 2015 Jan;47(1):13-21. Epub 2014 Nov17
14. Noon AP, Vlatkovic N, Polanski R, Maguire M, Shawki H, Parsons K, Boyd MT. p53 and MDM2 in renal cell carcinoma: biomarkers for disease progression and future therapeutic targets? Cancer. 2010 Feb 15;116(4):780-90
15. de Martino M, Gigante M, Cormio L, Prattichizzo C, Cavalcanti E, Gigante M, Ariano V, Netti GS, Montemurno E, Mancini V, Battaglia M, Gesualdo L, Carrieri G, Ranieri E. JAK3 in clear cell renal cell carcinoma: mutational screening and clinical implications. Urol Oncol. 2013 Aug;31(6):930-7
16. Stoehr CG, Stoehr R, Hartmann A, Hofstaedter F, Junker K, Blaszyk H, Wieland WF, Otto W, Denzinger S, Walter B. Mutational activation of FGFR3: no involvement in the development of renal cell carcinoma. J Cancer Res Clin Oncol. 2012 Feb;138(2):359-61
17. Porta C, Giglione P, Paglino C. Targeted therapy for renal cell carcinoma: focus on 2nd and 3rd line. Expert Opin Pharmacother 2016;17:643-55
18. Stoehr CG, Stoehr R, Hartmann A, Hofstaedter F, Junker K, Blaszyk H, Wieland WF, Otto W, Denzinger S, Walter B. Von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma. J Urol. 2008 Sep;180(3):860-5; discussion 865-6
19. Song Y, Huang J, Shan L, Zhang HT. Analyses of Potential Predictive Markers and Response to Targeted Therapy in Patients with Advanced Clear-cell Renal Cell Carcinoma. Chin Med J (Engl). 2015 Aug 5;128(15):2026-33
20. Huss S, Elges S, Trautmann M, Sperveslage J, Hartmann W, Wardelmann E. Classification of KIT/PDGFRA wild-type gastrointestinal stromal tumors: implications for therapy. Expert Rev Anticancer Ther. 2015 Jun;15(6):623-8
21. Huss S, Elges S, Trautmann M, Sperveslage J, Hartmann W, Wardelmann E. Tumor genetic analyses of patients with metastatic renal cell carcinoma and extended benefit from mTOR inhibitor therapy. Clin Cancer Res 2014;20:1955-64;
22. Kwiatkowski DJ, Choueiri TK, Fay AP, Rini BI, Thorner AR, de Velasco G, Tyburczy ME, Hamieh L, Albiges L, Agarwal N, Ho TH, Song J, Pignon JC, et al. Mutations in TSC1, TSC2, and MTOR Are Associated with Response to Rapalogs in Patients with Metastatic Renal Cell Carcinoma. Clin Cancer Res 2016 Feb 1